► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
Reckitt Benckiser is demerging its pharmaceuticals division with a planned listing of the renamed Indivior by Christmas. Lex’s Robert Armstrong and Oliver Ralph discuss why RB has split when there appears to be little value to unlock.
Make better investment decisions with Lex
http://www.ft.com/lex
Click here for more Lex videos
http://video.ft.com/Lex
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
Reckitt Benckiser is demerging its pharmaceuticals division with a planned listing of the renamed Indivior by Christmas. Lex’s Robert Armstrong and Oliver Ralph discuss why RB has split when there appears to be little value to unlock.
Make better investment decisions with Lex
http://www.ft.com/lex
Click here for more Lex videos
http://video.ft.com/Lex
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
Category
🗞
News